Copyright
©The Author(s) 2021.
World J Hepatol. Jan 27, 2021; 13(1): 144-150
Published online Jan 27, 2021. doi: 10.4254/wjh.v13.i1.144
Published online Jan 27, 2021. doi: 10.4254/wjh.v13.i1.144
Table 2 Difference in the incidence of hepatocellular carcinoma under long-term treatment with entecavir between genotype C and genotype D cirrhotic patients
| Incidence of HCC (%/yr) | P value | |
| Genotype C group (n = 8) | 2.91 ± 0.24 (SE) | P < 0.01 |
| Genotype D group (n = 5) | 1.89 ± 0.28 (SE) | P < 0.01 |
- Citation: Tarao K, Nozaki A, Chuma M, Taguri M, Maeda S. Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis. World J Hepatol 2021; 13(1): 144-150
- URL: https://www.wjgnet.com/1948-5182/full/v13/i1/144.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i1.144